Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation

British Journal of Haematology

Volumn 126, Issue 2, 2004, Pages 192-201

  Lai, F P L ^a   Cole Sinclair, M ^a   Cheng, W J ^a   Quinn, J M W ^b   Gillespie, M T ^b   Sentry, J W ^a   Schneider, H G ^a  

^a ALFRED HOSPITAL   (Australia)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Bone; Myeloma; Osteoclast; Osteoprotegerin; Receptor activator of nuclear factor B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIBODY; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR;

ANTIBODY DETECTION; ARTICLE; BONE; BONE MARROW BIOPSY; CANCER PATIENT; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CELL SECRETION; CELL STIMULATION; CLINICAL OBSERVATION; CONTROLLED STUDY; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; IN VITRO STUDY; MONONUCLEAR CELL; MULTINUCLEAR CELL; MYELOMA CELL; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SECRETION; PURIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSLATION; STROMA CELL; TUMOR CELL LINE;

ACID PHOSPHATASE; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; OSTEOCLASTS; PROTEIN ISOFORMS; PROTEOGLYCANS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNDECANS; TUMOR CELLS, CULTURED;

EID: 3242662500     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05018.x     Document Type: Article

References (32)

1. Abe, M., Hiura, K., Wilde, J., Moriyama, K., Hashimoto, T., Ozaki, S., Wakatsuki, S., Kosaka, M., Kido, S., Inoue, D. & Matsumoto, T. (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood, 100, 2195-2202.
2. Barille-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P.L., Epstein, J., Fenton, R.G., Jacobson, J., Kuehl, W.M., Shaughnessy, J. & Tricot, G. (2003) Advances in biology and therapy of multiple myeloma. Hematology (American Society of Hematology. Education Program), 1, 248-278.
3. Callander, N.S. & Roodman, GD. (2001) Myeloma bone disease. Seminars in Hematology, 38, 276-285.
4. Choi, Y., Woo, K.M., Ko, S.H., Lee, Y.J., Park, S.J., Kim, H.M. & Kwon, B.S. (2001) Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. European Journal of Immunology, 31, 2179-2188.
5. Croucher, P.I., Shipman, C.M., Lippitt, J., Perry, M., Asosingh, K., Hijzen, A., Brabbs, A.C., van Beek, E.J., Holen, I., Skerry, T.M., Dunstan, C.R., Russell, G.R., Van Camp, B. & Vanderkerken, K. (2001) Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood, 98, 3534-3540.
6. Dalton, W.S., Bergsagel, P.L., Kuehl, W.M., Anderson, K.C. & Harousseau, J.L. (2001) Multiple myeloma. Hematology (American Society of Hematology. Education Program), 1, 157-177.
7. Deyama, Y., Kikuiri, T., Ohnishi, G., Feng, Y.G., Takeyama, S., Hatta, M., Yoshimura, Y. & Suzuki, K. (2002) Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts. Biochemical and Biophysical Research Communications, 298, 240-246.
8. Farrugia, A.N., Atkins, G.J., To, L.B., Pan, B., Horvath, N., Kostakis, P., Findlay, D.M., Bardy, P. & Zannettino, A.C. (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Research, 63, 5438-5445.
9. Fata, J.E., Kong, Y.Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R.A., Elliott, R., Scully, S., Voura, E.B., Lacey, D.L., Boyle, W.J., Khokha, R. & Penninger, J.M. (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell, 103, 41-50.
10. Giuliani, N., Bataille, R., Mancini, C., Lazzaretti, M. & Barille, S. (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood, 98, 3527-3533.
11. Han, J.H., Choi, S.J., Kurihara, N., Koide, M., Oba, Y. & Roodman, G.D. (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood, 97, 3349-3353.
12. Heider, U., Langelotz, C., Jakob, C., Zavrski, I., Fleissner, C., Eucker, J., Possinger, K., Hofbauer, L.C. & Sezer, O. (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clinical Cancer Research, 9, 1436-1440.
13. Kartsogiannis, V., Zhou, H., Horwood, N.J., Thomas, R.J., Hards, D.K., Quinn, J.M., Niforas, P., Ng, K.W., Martin, T.J. & Gillespie, M.T. (1999) Localization of RANKL (receptor activator of NFκB ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone, 25, 525-534.
14. Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., Nakagawa, N., Kinosaki, M., Yamaguchi, K., Shima, N., Yasuda, H., Morinaga, T., Higashio, K., Martin, T.J. & Suda, T. (2000) Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. Journal of Experimental Medicine, 191, 275-286.
15. Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A.J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J. & Penninger, J.M. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315-323.
16. Kong, Y.Y., Boyle, W.J. & Penninger, J.M. (2000) Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunology Today, 21, 495-502.
17. Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., Elliott, R., Colombero, A., Eiliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y.X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J. & Boyle, W.J. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93, 165-176.
18. Manabe, N., Kawaguchi, H., Chikuda, H., Miyaura, C., Inada, M., Nagai, R., Nabeshima, Y., Nakamura, K., Sinclair, A.M., Scheuermann, R.H. & Kuro-o, M. (2001) Connection between B lymphocyte and osteoclast differentiation pathways. Journal of Immunology, 167, 2625-2631.
19. Pearse, R.N., Sordillo, E.M., Yaccoby, S., Wong, B.R., Liau, D.F., Colman, N., Michaeli, J., Epstein, J. & Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 98, 11581-11586.
20. Polek, T.C., Talpaz, M., Darnay, B.G. & Spivak-Kroizman, T. (2003) TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. Journal of Biological Chemistry, 278, 32317-32323.
21. Quinn, J.M., Elliott, J., Gillespie, M.T. & Martin, T.J. (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology, 139, 4424-4427.
22. Roux, S., Meignin, V., Quillard, J., Meduri, G., Guiochon-Mantel, A., Fermand, J.P., Milgrom, E. & Mariette, X. (2002) RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. British Journal of Haematology, 117, 86-92.
23. Seidel, C., Hjertner, O., Abildgaard, N., Heickendorff, L., Hjorth, M., Westin, J., Nielsen, J.L., Hjorth-Hansen, H., Waage, A., Sundan, A. & Borset, M. (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood, 98, 2269-2271.
24. Sezer, O., Heider, U., Jakob, C., Eucker, J. & Possinger, K. (2002) Human bone marrow myeloma cells express RANKL. Journal of Clinical Oncology, 20, 353-354.
25. Simonet, W.S., Lacey, D.L., Dunstan, C.R., Kelley, M., Chang, M.S., Luthy, R., Nguyen, H.Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H.L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T.M., Hill, D., Pattison, W., Campbell, P. & Boyle, W.J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89, 309-319.
26. Standal, T., Seidel, C., Hjertner, O., Plesner, T., Sanderson, R.D., Waage, A., Borset, M. & Sundan, A. (2002) Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood, 100, 3002-3007.
27. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M.T. & Martin, T.J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Reviews, 20, 345-357. Review.
28. Takahashi, N., Udagawa, N. & Suda, T. (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochemical and Biophysical Research Communications, 256, 449-455. Review.
29. Terpos, E., Politou, M., Szydlo, R., Goldman, J.M., Apperley, J.F. & Rahemtulla, A. (2003) Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology, 123, 106-109.
30. Tricot, G. (2000) New insights into role of microenvironment in multiple myeloma. Lancet, 355, 248-250.
31. Uneda, S., Hata, H., Matsuno, F., Harada, N., Mitsuya, Y., Kawano, F. & Mitsuya, H. (2003) Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. British Journal of Haematology, 120, 53-55.
32. Worel, N., Greinix, H., Ackermann, J., Kaufmann, H., Urbauer, E., Hocker, P., Gisslinger, H., Lechner, K., Kalhs, P. & Drach, J. (2001) Deletion of chromosome 13q14 detected by fluorescence in situ hybridization has prognostic impact on survival after high-dose therapy in patients with multiple myeloma. Annals of Hematology, 80, 345-348.